Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours—results from a Turkish multi-centre study

Basit Öğe Kaydı
dc.contributor.authorOlmez O.F.
dc.contributor.authorBilici A.
dc.contributor.authorEr O.
dc.contributor.authorBisgin A.
dc.contributor.authorSevinc A.
dc.contributor.authorAkman T.
dc.contributor.authorUslu R.
dc.date.accessioned2024-08-31T07:42:32Z
dc.date.available2024-08-31T07:42:32Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: The objective of this multi-centre, real-world study was to examine the potential influence of comprehensive molecular profiling on the development of treatment decisions or adjustments for patients with advanced solid malignancies. We then evaluated the impact of these informed choices on patient treatment outcomes. Methods: The study encompassed 234 adult patients (mean age: 52.7 ± 14.3 years, 54.7% women) who were diagnosed with solid tumours at 21 different medical centres in Turkey. Remarkably, 67.9% of the patients exhibited metastasis at the time of diagnosis. We utilized an OncoDNA (Gosselies, Belgium) platform (OncoDEEP) integrating next-generation sequencing with additional tests to harvest complex molecular profiling data. The results were analyzed in relation with two specific outcomes: (i) the impact on therapeutic decisions, including formulation or modifications, and (ii) associated treatment response. Results: Out of the 228 patients with final molecular profiling results, 118 (50.4%) had their treatment modified, whilst the remaining 110 (47.0%) did not. The response rates were comparable, with 3.9 versus 3.4% for complete response, 13.6 versus 29.3% for partial response, 66.9 versus 51.7% for progressive disease and 15.5 versus 15.5% for stable disease for treatments informed and not informed by complex molecular profiling, respectively (P = 0.16). Conclusion: Our real-world findings highlight the significant impact of complex molecular profiling on the treatment decisions made by oncologists for a substantial portion of patients with advanced solid tumours. Regrettably, no significant advantage was detected in terms of treatment response or disease control rates. © The Author(s) 2024. Published by Oxford University Press. All rights reserved.en_US
dc.identifier.doi10.1093/jjco/hyae002
dc.identifier.endpage568en_US
dc.identifier.issn0368-2811
dc.identifier.issue5en_US
dc.identifier.pmid38271177en_US
dc.identifier.scopus2-s2.0-85192428470en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage562en_US
dc.identifier.urihttps://doi.org/10.1093/jjco/hyae002
dc.identifier.urihttps://hdl.handle.net/11454/103926
dc.identifier.volume54en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofJapanese Journal of Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240831_Uen_US
dc.subjectadvanced solid tumoursen_US
dc.subjectcomplex molecular profilingen_US
dc.subjectnext-generation sequencingen_US
dc.subjecttherapeutic planningen_US
dc.subjecttreatment responseen_US
dc.titleBeyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours—results from a Turkish multi-centre studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu